

# Antioxidants in Cancer Therapy; Their Actions and Interactions With Oncologic Therapies

by **Davis W. Lamson, MS, ND**  
and **Matthew S. Brignall, ND**

## Abstract

There is a concern that antioxidants might reduce oxidizing free radicals created by radiotherapy and some forms of chemotherapy, and thereby decrease the effectiveness of the therapy. The question has arisen whether concurrent administration of oral antioxidants is contraindicated during cancer therapeutics. Evidence reviewed here demonstrates exogenous antioxidants alone produce beneficial effects in various cancers, and except for a few specific cases, animal and human studies demonstrate no reduction of efficacy of chemotherapy or radiation when given with antioxidants. In fact, considerable data exists showing increased effectiveness of many cancer therapeutic agents, as well as a decrease in adverse effects, when given concurrently with antioxidants.

*Altern Med Rev* 1999;4(5):304-329

## Introduction

Dietary and endogenous antioxidants prevent cellular damage by reacting with and eliminating oxidizing free radicals. However, in cancer treatment, a mode of action of certain chemotherapeutic agents involves the generation of free radicals to cause cellular damage and necrosis of malignant cells. So a concern has logically developed as to whether exogenous antioxidant compounds taken concurrently during chemotherapy could reduce the beneficial effect of chemotherapy on malignant cells. The importance of this concern is underlined by a recent study which estimates 23 percent of cancer patients take antioxidants.<sup>1</sup>

The study of antioxidant use in cancer treatment is a rapidly evolving area. Antioxidants have been extensively studied for their ability to prevent cancer in humans.<sup>2</sup> This paper reviews the use of antioxidants as a therapeutic intervention in cancer patients, and their potential interactions with radiation and chemotherapy. There has been significant investigation of this area, with promising findings which indicate continuing investigation is warranted. For further discussion of the use of antioxidants as sole cancer therapy, refer to the review article by Prasad published earlier this year.<sup>3</sup> A number of reports show a reduction in adverse effects of chemotherapy when given concurrently with antioxidants. These data are more completely summarized by Weijl et al.<sup>4</sup>

---

Davis W. Lamson, MS, ND  
Private practice, Tahoma Clinic- Kent, WA. Coordinator of Oncology, Bastyr University- Kenmore, WA. Correspondence Address: 9803 17th Ave. NE, Seattle, WA. 98115.

Matthew S. Brignall, ND  
1999 graduate, Bastyr University. Currently doing a research fellowship at Tahoma Clinic in Kent, WA.  
e-mail: mattandmolly@w-link.net

## Conflicting Views of Antioxidant Use in Cancer Therapy

It was suggested in a recent publication that no supplementary antioxidants be given concurrently with chemotherapy agents which employ a free radical mechanism.<sup>5</sup> The paper must be commended for pointing out that the combination of antioxidants and chemotherapy agents needs more investigation, and should serve as a wake-up call regarding how much we need further definition of the actions of specific antioxidants with chemotherapeutic agents. However, it should not serve as scientific closure on an adjunctive treatment of possible great promise in cancer therapy.

The present authors are by no means recommending any lack of caution about use of antioxidants. On the contrary, published research indicates the cautious and judicious use of a number of antioxidants can be helpful in the treatment of cancer; as sole agents and as adjuncts to standard radiation and chemotherapy protocols.

It was suggested that antioxidants might interfere with the oxidative mechanisms of alkylating agents.<sup>5</sup> These drugs create substantial DNA damage, resulting in cell necrosis. However, recent evidence indicates a sizeable amount of chemotherapy damage is by other mechanisms, which trigger apoptosis.<sup>6</sup> Antioxidants have been shown to increase cell death by this mechanism.<sup>7,8</sup> Given this, any argument that antioxidants are likely to interfere with most chemotherapy is too simplistic and probably untrue.

Numerous animal studies have been published demonstrating decreased tumor size and/or increased longevity with the combination of chemotherapy and antioxidants.<sup>7,9-16</sup> A recent study was conducted on small-cell lung cancer in humans using combination chemotherapy of cyclophosphamide, Adriamycin (doxorubicin), and vincristine with radiation and a combination of antioxidants, vitamins,

trace elements, and fatty acids. The conclusion was "antioxidant treatment, in combination with chemotherapy and irradiation, prolonged the survival time of patients" compared to expected outcome without the composite oral therapy.<sup>17</sup> Two human studies found melatonin plus chemotherapy to induce greater tumor response than chemotherapy alone.<sup>18,19</sup> The treatments producing these positive results would have been advised against by those advocating no antioxidant use during chemotherapy. These studies will be discussed in more detail below.

It is the opinion of the authors of this paper that interactions between antioxidants and chemotherapeutics cannot be predicted solely on the basis of presumed mechanism of action. The fact remains that physicians must be aware of the available research to help their patients take advantage of positive interactions existing between antioxidants and chemotherapy or radiation.

Additionally, physicians need to remain aware of the large body of evidence showing a positive effect of antioxidants in the period following chemotherapy administration. The general protocol with standard oncologic therapies is to follow a watch-and-wait strategy after therapeutic administration is concluded. This is a period when supplemental therapies are highly indicated and have been demonstrated to result in a higher percentage of successful outcomes.<sup>20,21</sup>

## Overview of Cancer Therapeutic Agents

Chemotherapy agents can be divided into several categories: alkylating agents (e.g., cyclophosphamide, ifosfamide), antibiotics which affect nucleic acids (e.g., doxorubicin, bleomycin), platinum compounds (e.g., cisplatin), mitotic inhibitors (e.g., vincristine), antimetabolites (e.g., 5-fluorouracil), camptothecin derivatives (e.g., topotecan),

## CATEGORIES OF CHEMOTHERAPEUTICS

- ◆ Alkylating agents (e.g., cyclophosphamide, ifosamide)
- ◆ Antibiotics affecting nucleic acids (e.g., doxorubicin, bleomycin)
- ◆ Platinum compounds (e.g., cisplatin)
- ◆ Mitotic inhibitors (e.g., vincristine)
- ◆ Antimetabolites (e.g., 5-fluorouracil)
- ◆ Camptothecin derivatives (e.g., topotecan, etoposide)
- ◆ Biological response modifiers (e.g., interferon)
- ◆ Hormone therapies (e.g., tamoxifen)

biological response modifiers (e.g., interferon), and hormone therapies (e.g., tamoxifen). The agents most noted for creating cellular damage by initiating free radical oxidants are the alkylating agents, the tumor antibiotics, and the platinum compounds. The agents in these categories demand definition concerning interactions with antioxidants which might reduce effectiveness of chemotherapy. There is also the possibility of adverse interaction between antioxidant treatment and agents that do not act via an oxidative mechanism (e.g., 5-fluorouracil or tamoxifen).

In addition to the idea that chemotherapy must create a lethal injury to DNA to produce malignant cell death is the mechanism of apoptosis. A dose of chemotherapy which does not produce necrosis can trigger apoptosis, either immediate or delayed. Additionally, anti-apoptotic mutations can result in drug resistance in human tumors. At least one antioxidant (quercetin) has been demonstrated to overcome such an anti-apoptotic blockage.<sup>22</sup>

Radiotherapy uses ionizing radiation to produce cell death through free radical formation. Two mechanisms are involved. The apoptosis mechanism results in cell death within a few hours of radiation. The second mechanism is radiation-induced failure of mitosis and the inhibition of cellular proliferation, which kills cancer cells. Currently, the principal target of radiation is considered to be cellular DNA. However, studies show the signal for apoptosis can be generated by the effect of radiation on cell membranes, apparently through lipid peroxidation. This suggests an alternate mechanism to the hypothesis that

DNA damage is required for cell death.<sup>23</sup>

### Vitamin A and Carotenoids as Cancer Treatment

Many research reports on the anti-cancer properties of vitamin A and the related retinoids have been published

over the last 20 years. Most of these studies examined all-trans retinoic acid (RA). RA is formed in human tissues from beta-carotene and retinol, does not accumulate in the liver, thus it is not associated with significant hepatotoxicity.<sup>24</sup> Treatment with RA is associated with many side effects, including headache, lethargy, anorexia, vomiting, and visual disturbance.<sup>24</sup> Another retinoid used in cancer treatment is 13-Cis-retinoic acid (cRA), also known as isotretinoin.<sup>25</sup>

RA *in vitro* demonstrates growth inhibitory activity against at least 14 types of human cancers.<sup>24</sup> Acute promyelocytic leukemia (APL) has been shown to respond well to RA, but not to cRA.<sup>26</sup> In one study, nine of 11 patients with APL entered complete remission after treatment with 45 mg/m<sup>2</sup> daily oral dose of RA.<sup>27</sup> Similar results are reported elsewhere,<sup>28,29</sup> and have been confirmed *in vitro*.<sup>30</sup>

Local application of an RA-containing cream demonstrated low toxicity and some histological improvement of cervical intraepithelial neoplasia II (CIN II) in a phase I study.<sup>31</sup> In a phase III trial, RA led to complete regression of CIN II in 42 percent of women compared with 27 percent in the placebo group.<sup>32</sup> No significant effect was noted in severe cervical dysplasia.<sup>32</sup> After remission induced by conventional therapy, treatment

with cRA is associated with fewer second primary tumors in head and neck squamous-cell carcinoma.<sup>33</sup>

Retinoic acid decreased the growth rate and increased differentiation of human small cell lung cancer lines *in vitro*.<sup>34</sup> Daily oral administration of 300,000 IU vitamin A as retinol palmitate led to a significant reduction in second primary tumors and an increase in disease-free survival post-surgery in stage I lung cancer.<sup>35</sup> However, a small trial of cRA at 200 mg/day found no appreciable benefit in the treatment of advanced non-small cell lung cancer. Of 23 patients evaluated in this trial, only one achieved a partial response to treatment.<sup>36</sup>

A trial of oral vitamin A at 100,000 IU/day in patients with resected malignant melanoma found no survival benefit compared with those taking placebo.<sup>37</sup> In a trial of oral RA for hormone-refractory prostate cancer, dosed 45 mg/m<sup>2</sup> daily, only a 15-percent response rate was seen.<sup>38</sup> It is clear from these data that the effects of the retinoids as sole therapeutic agents are limited, perhaps mainly to hematologic malignancies, which tend to develop RA resistance over time.<sup>28</sup> For further information on the use of retinoids in cancer therapy, refer to the review by MA Smith, et al.<sup>24</sup>

In contrast to the retinoids, comparatively little is known about the use of carotenoids as anti-cancer agents *in vivo*. The interest in carotenoids mainly stems from the extensive epidemiological evidence associating dietary intake with lower incidences of many cancer types.<sup>39</sup> Alpha- and beta-carotene have been examined for *in vitro* tumor inhibitory activity against human neuroblastoma cell lines, and alpha-carotene was found to have 10 times the anti-tumor activity of beta-carotene.<sup>40</sup> Currently there is some concern regarding supplementation with carotenoids, as beta-carotene has been associated with higher risk of lung cancer in smokers,<sup>41</sup> but not in the general population.<sup>42</sup>

Aside from this concern, high doses of beta-carotene, even over long periods of time, are not associated with serious toxicity.<sup>39</sup>

There are also promising data showing chemopreventative activity of the carotenoid lycopene against prostate cancer.<sup>43</sup> *In vitro* work suggests lycopene can induce differentiation, with vitamin D3, in human leukemia cells.<sup>44</sup> One study showed lycopene to be a stronger inhibitor of human cancer cell proliferation *in vitro* than alpha- or beta-carotene.<sup>45</sup> As yet, human trials are lacking on the use of lycopene.

### Vitamin A and Carotenoids with Radiation

Evidence exists to support the use of retinoids concomitantly with radiotherapy. *In vitro* studies have shown retinoic acid (RA) causes radiosensitization in human tumor cell lines at concentrations which do not cause cellular toxicity. This effect was reversible with removal of RA.<sup>46</sup> In mice bearing human breast adenocarcinoma tumor lines, the effect of local radiation was enhanced by supplemental vitamin A (150,000 IU) and beta-carotene (90 mg/kg) given during treatment. The beneficial effect of the supplemental treatment was noted as decreased tumor size and increased survival time. Supplemental vitamin A and beta-carotene plus radiation had significantly greater anti-tumor effect than radiation or supplementation alone. The effect of vitamin A was not significantly different from beta-carotene.<sup>9</sup>

In a randomized trial of oral vitamin A (1.5 million IU/day) plus radiotherapy for advanced cervical cancer, vitamin A plus radiotherapy significantly increased T-cell response and non-significantly reduced relapse rates compared with those undergoing radiotherapy only.<sup>46</sup> A pilot human study of cis-retinoic acid (cRA) with radiotherapy and interferon- $\alpha$ 2a on locally advanced cervical cancer noted a 47-percent tumor response and

33-percent complete remission rate, with no grade 3 or 4 toxicity noted. Historical controls without cRA treatment had a 42-percent tumor response rate and only 17-percent complete remissions.<sup>47</sup> The ability of vitamin A to increase tumor response to radiation while reducing toxicity has been theorized to be due to the stimulation of immune response to tumor tissue.<sup>48</sup>

In a human study, beta-carotene at 75 mg daily during radiation treatment for advanced squamous cell carcinoma of the mouth significantly reduced the incidence of severe mucositis reactions without causing noticeable side effects. The remission rate was unchanged by beta-carotene treatment.<sup>49</sup> *In vitro* evidence suggests synthetic beta-carotene does not have the radioprotective effect noted with the natural form.<sup>50</sup> The meaning of this finding is as yet unclear.

### Vitamin A and Carotenoids with Chemotherapy

Perhaps more than any other antioxidant treatment, retinoids are increasingly being pursued as adjunctive treatment to standard chemotherapeutics. Most evidence suggests an increased cytotoxic effect with reduced toxicity. *In vitro* studies using human small cell lung cancer lines demonstrated that incubation with retinoic acid (RA) led to an increased sensitivity to etoposide, but more resistance to doxorubicin.<sup>51</sup> Human synovial sarcoma cells exposed to RA *in vitro* were found to have enhanced response to doxorubicin, vincristine, and especially cisplatin.<sup>52</sup> Although the potential adverse interaction with doxorubicin was not confirmed in the latter study, this is an area that merits further definition.

In studies of mice with transplanted human breast tumor tissue, concurrent treatment of either vitamin A or beta-carotene with cyclophosphamide led to a significantly greater tumor response and survival time

compared to cyclophosphamide treatment alone. The effect of beta-carotene was roughly equivalent to that of vitamin A.<sup>9</sup> Also in mice, co-administration of vitamin A with methotrexate ameliorated intestinal damage, without inhibiting its *in vivo* anti-tumor activity.<sup>53</sup>

In a phase I human trial of cisplatin with 13-cis-retinoic acid (cRA), the two agents were noted to have strong synergism against head and neck squamous cell carcinoma. Of 10 evaluable patients, all had complete tumor response at the primary site. Dosages of 20 mg/day cRA were well tolerated, but severe toxicities were seen at 40 mg/day.<sup>54</sup> Extremely high oral doses of RA (150 mg/m<sup>2</sup> daily) showed no inhibitory effect on the activity of cisplatin and etoposide on small cell lung carcinoma in humans. This dose also was not associated with any therapeutic benefit, and needed to be discontinued in a majority of patients due to side effects.<sup>55</sup> Vitamin A palmitate at an oral dose of 50,000 IU twice daily, plus b-interferon and combined chemotherapy (epirubicin, mitomycin C, and 5-fluorouracil) prolonged symptom palliation in 35 percent of pancreatic cancer patients. This treatment was associated with severe toxicities in several systems, but only hepatotoxicity was thought to be associated with the addition of retinoids.<sup>56</sup> Sequential treatment of non-lymphocytic leukemia patients with conventional chemotherapy, followed by 16,000 IU/day of retinol palmitate led to a further induction of maturation in blast cells than seen with chemotherapy alone. In three of four patients undergoing this sequential therapy, complete remission resulted.<sup>57</sup> Addition of 400,000 IU/week vitamin A to a conventional chemotherapy regimen (doxorubicin, bleomycin, 5-fluorouracil, and methotrexate) led to improved survival with less than the expected severity of side effects compared with historical controls.<sup>10</sup>

Although the relative lack of toxicity compared to the retinoids makes it an attractive option, beta-carotene in combination with chemotherapy is a largely unexplored area. In mice, beta-carotene co-administration led to increased tumor growth delay with doxorubicin and etoposide, and increased tumor cell killing with cyclophosphamide in solid tumors. The co-administration of beta-carotene and 5-fluorouracil, however, reduced tumor growth delay in murine fibrosarcomas, but not in squamous cell carcinomas.<sup>58</sup> Data on other carotenoids is lacking.

### Vitamin C as Cancer Treatment

The use of vitamin C in the treatment of cancer has been the source of many claims and controversies over the last 25 years. Initial reports from Drs. Pauling and Cameron were promising, and gained much notoriety. They reported 100 cases of terminal cancer, independently assessed and refractory to conventional treatment, who lived on average four times longer than 1000 age- and disease-matched controls.<sup>59</sup> The protocol included intravenous and oral administration, and is described in detail elsewhere.<sup>60</sup> Prospective randomized trials held at the Mayo Clinic were unable to replicate these results, finding negligible difference between treated patients and controls in survival time.<sup>61,62</sup> These results were criticized on a number of grounds, including

### VITAMIN A SUMMARY

- ◆ Retinoic acid has been shown to be a promising treatment for acute promyelocytic leukemia.
- ◆ Vitamin A and beta-carotene increase radiation's effect *in vivo*, and vitamin A improves response rate in humans.
- ◆ Vitamin A and beta-carotene increase the effect of cyclophosphamide *in vivo*.
- ◆ Addition of vitamin A to combined chemotherapy has led to increased response in two human studies.
- ◆ Vitamin A has been shown *in vivo* not to interfere with methotrexate, cisplatin, and etoposide.
- ◆ No *in vivo* evidence suggests that vitamin A reduces the effect of chemotherapy.
- ◆ Beta-carotene has been shown *in vivo* not to interfere with doxorubicin or etoposide.
- ◆ *Beta-carotene has been shown to reduce the effect of 5-fluorouracil on one tumor type in vivo.*

the noticeable difference between the vitamin C and placebo, lack of intravenous administration, and termination of treatment with tumor progression.<sup>60</sup> Later *in vitro* and *in vivo* research, and well documented case reports,<sup>63</sup> suggest a vitamin C dose much higher than that used in the Pauling/Cameron studies can actually be cytotoxic to tumors without

damaging normal cells. The required tissue concentrations are thought to only be reachable with intravenous doses over long periods of time. This research, as well as the proposed mechanism of action, is examined elsewhere.<sup>64</sup> Vitamin C is generally well-tolerated by healthy people, even in doses as high as 200 g/day IV.<sup>64,65</sup> Dr. Cameron has noted that a small percentage of cancer patients will respond to vitamin C with rapidly proliferating and disseminating tumors.<sup>66</sup> Other investigators have not noted this effect.

### Vitamin C with Radiation

Quite surprisingly, no published studies have looked at the effect of doses over five grams of oral or intravenous vitamin C on radiotherapy in humans. It has been shown, however, that cancer patients have a significant elevation in plasma and leukocyte ascorbate levels after radiotherapy compared with pretreatment levels without any change in dietary intake.<sup>67</sup>

In mice, vitamin C (1 g/kg), given intraperitoneally with vitamin K3 (10 mg/kg), increased the therapeutic effect of radiation on solid tumors without causing any signs of toxicity due to the vitamins.<sup>68</sup> In another mouse study, a single intraperitoneal dose of 4.5 g/kg vitamin C was not cytotoxic to normal tissue and did not change the radiation effect on tumor tissue. The lethal dose of radiation increased and skin desquamation reaction was reduced by ascorbate treatment. It should be noted that these vitamin C doses are much greater than have been used historically in humans.<sup>69</sup> The radioprotection of healthy tissue and radiosensitizing effect in tumors with use of ascorbate were confirmed in two other mouse tumor models.<sup>70,71</sup>

A randomized trial with 50 human subjects looked at the effect of concurrent vitamin C (five daily doses of 1 g each) and radiotherapy on different tumor types. More complete responses to radiation were noted in the vitamin C group at one month (87% to 55%) and four months (63% to 45%) post treatment. Side effects tended to be fewer in the ascorbate-treated subjects as well. Plasma levels of ascorbate in the treatment group were greater than control subjects, but less than the mean of 20 healthy subjects tested.<sup>72</sup> It remains to be investigated whether continuing treatment beyond the end of radiotherapy or use of a higher dose would improve these results. A double-blind trial of topical vitamin C solution for the prevention of radiation dermatitis failed to find any beneficial effect. The trial did not examine the absorption of the aqueous preparation, although previous trials showed about 12 percent of the vitamin C penetrated into the epidermis.<sup>73</sup>

### Vitamin C with Chemotherapy

Vitamin C has been extensively tested *in vitro* and *in vivo* for its ability to prevent the adverse effects of, decrease resistance to, and increase the effects of chemotherapeutic

agents. Co-treatment with doxorubicin and vitamin C (2 mg/kg) led to a reduction in the toxicity seen with doxorubicin alone in mice and guinea pigs. The prevention of cardiomyopathy was confirmed by electron microscopy. Treatment with ascorbic acid was not associated with decreased effect of doxorubicin, and was associated with an increased life span compared with doxorubicin treatment alone.<sup>11</sup> *In vitro* experiments do suggest, however, that vitamin C does enhance doxorubicin resistance in human breast cancer cell lines already known to be resistant. It did not lead to resistance in cells which were doxorubicin-sensitive.<sup>74</sup> Vitamin C at non-cytotoxic concentrations (1 mM) increased the activity of doxorubicin, cisplatin, and paclitaxel in human breast carcinoma cells *in vitro*. This effect was particularly marked and synergistic with doxorubicin. The authors note that since vitamin C has already shown an ability to reduce the cardiotoxicity of doxorubicin, ascorbic acid and doxorubicin are

### VITAMIN C SUMMARY

- ◆ Vitamin C increases the effect of radiotherapy in humans and in mice.
- ◆ Vitamin C increases the effect of cyclophosphamide, vinblastine, doxorubicin, 5-fluorouracil, procarbazine, and asparaginase *in vivo*.
- ◆ Co-administration of vitamin K may increase both of the above activities of vitamin C.
- ◆ Vitamin C has been shown to increase the effect of cisplatin and paclitaxel *in vitro*.
- ◆ No *in vivo* evidence suggests that vitamin C decreases the effect of chemotherapy.
- ◆ *Vitamin C may increase the resistance to doxorubicin in resistant breast cancer cells.*

an attractive future treatment for breast cancer.<sup>75</sup>

Vitamin C has been shown to increase the drug accumulation and decrease resistance to vincristine in human non-small-cell lung cancer cells *in vitro*. An ascorbic acid-sensitive uptake mechanism was theorized to explain these results.<sup>76</sup>

Combined intraperitoneal administration of vitamin C (1g/kg) and vitamin K (10 mg/kg) given prior to chemotherapy increased survival and the effect of several chemotherapeutic agents (cyclophosphamide, vinblastine, doxorubicin, 5-fluorouracil, procarbazine, and asparaginase) in a murine ascitic liver tumor model. The vitamin combination did not increase the toxicity of these agents to healthy tissue. Splenic and thymic weights of the vitamin-treated animals were higher than those receiving cytotoxic treatment alone, suggesting an immune-stimulating action of the vitamins.<sup>12</sup> These results have yet to be confirmed in humans.

### Vitamin E as Cancer Treatment

Vitamin E succinate (VES, alpha tocopherol succinate), has generated some interest as an adjunctive cancer therapy recently. VES demonstrated growth inhibition of human B-cell lymphoma<sup>77</sup> and estrogen receptor-negative breast cancer<sup>78</sup> cell lines *in vitro*. Vitamin E at 3 mM concentration arrested tumor cells in the G<sub>1</sub> phase of the cell cycle, leading to apoptosis.<sup>7</sup> Recent research on human oral squamous carcinoma cells suggests the VES effect is biphasic; growth stimulatory at physiological concentrations, while pharmacological concentrations are inhibitory.<sup>79</sup> A phase I trial of intravenous vitamin E in treatment refractory neuroblastoma found mild toxicity (tendency toward increased bleeding time was noted) at doses below 2,300 mg/m<sup>2</sup>. Five of 13 patients experienced pain relief and/or tumor regression with treatment. No complete remissions resulted from treatment.<sup>80</sup> Vitamin

E, 200 mg daily, given together with 18 g/day omega-3 fatty acids from fish oil, prolonged survival in patients with generalized malignancy in a randomized controlled trial. Improvement in T-helper/suppressor ratio was also noted with treatment.<sup>81</sup> Phase I clinical trials are being planned or are underway in patients with breast and prostate cancers.<sup>82</sup> Vitamin E and its derivatives are particularly attractive therapeutic agents due to their remarkable lack of toxicity *in vivo*.<sup>83</sup>

### Vitamin E with Radiation

The picture here is unfortunately far from clear. An initial report showed mice treated with 1 g/kg of vitamin E had an increased in the lethal radiation dose (LD50). Unfortunately, squamous cell carcinoma cell lines treated in this study were less radiosensitive, with 35-percent cell survival versus 13 percent in controls.<sup>84</sup> A later experiment was able to replicate this finding *in vitro* in cells incubated for several weeks with vitamin E, but not those in which it was added immediately before irradiation.<sup>85</sup> The latest experiment to look at this issue actually found that some doses of vitamin E enhanced mouse sarcoma tumor cell kill. Intraperitoneal pretreatment with 50, 250, and 500 mg/kg, but not 1000 mg/kg, led to better tumor response than radiation alone. The authors also noted that intramuscular and oral tocopherol administration had a similar effect.<sup>86</sup> From these results it would appear vitamin E doses used in humans increase the effect of radiotherapy, and super-human doses (above 35,000 IU) may blunt the therapeutic efficacy of radiotherapy.

Radiation-induced fibrosis is a sequela to irradiation therapy which does not spontaneously regress. A combination of vitamin E (1000 IU/day) and pentoxifylline (800 mg/day) completely reversed a case of radiation-induced cervicothoracic fibrosis in a 67-year-old woman after an 18-month course of treatment. The findings were confirmed with CT



scan. A phase II trial is currently underway to confirm these results.<sup>87</sup>

### Vitamin E with Chemotherapy

There are a few interesting recent reports on the concurrent use of vitamin E with chemotherapy.

Vitamin E, 750 mg/kg intraperitoneally, given with 5-fluorouracil had a greater anti-tumor effect in mice bearing human colon cancer lines than either agent alone; treatment led to complete cessation of tumor growth. The same investigators found *in vitro* addition of vitamin E to either 5-fluorouracil or doxorubicin enhances the effect of these agents on human colon cancer cells.<sup>7</sup> Another report showed pretreatment with 85 mg (approximately 4000 mg/kg) alpha-tocopherol reduced the lethality of a single 15 mg/kg dose of doxorubicin from 85 percent to 10 percent in mice. This dose of tocopherol did not alter the suppression of tumor cell DNA synthesis by doxorubicin. The tumor-bearing mice pretreated with vitamin E lived longer on average than those treated with doxorubicin alone. The authors theorized the vitamin E blocked lipid peroxidation-mediated toxicity, while not impairing the anti-tumor property of doxorubicin.<sup>14</sup> Both the toxicity prevention effect and the lack of inhibition of vitamin E toward doxorubicin were confirmed in a later experiment.<sup>88</sup> *In vitro* experiments showed VES can enhance the cytotoxic effect of doxorubicin on human prostate cancer cells at concentrations easily attained in human plasma (5 mg/ml). This inhibition was found to be dose-dependent.<sup>89</sup> Oral and

### VITAMIN E SUMMARY

- ◆ Vitamin E induces apoptosis in experimental tumor lines.
- ◆ Vitamin E with omega-3 fatty acids increased survival time in terminal cancer patients.
- ◆ Vitamin E in doses below 500 mg/kg (approximately 35,000 IU human dose) may increase the effect of radiotherapy in mice.
- ◆ Vitamin E increases the activity of 5-fluorouracil, doxorubicin, and cisplatin *in vivo*.
- ◆ No evidence exists that vitamin E reduces the effect of chemotherapy *in vivo*.

intraperitoneal administration of vitamin E (20 mg/kg/day) enhanced the anti-tumor activity of cisplatin on neuroblastoma in mice.<sup>90</sup>

### Selenium as Cancer Treatment

The use of selenium compounds as a cancer treatment predates most conventional treatments currently in use.<sup>91</sup> In spite of this, comparatively little is known regarding the use of selenium as a cancer therapy in living systems. Subcutaneous injection of 2 mcg/g selenium into tumor-bearing mice led to a 75-percent reduction in tumor mass compared to controls.<sup>92</sup> This inhibitory effect of selenium was confirmed in human breast cancer cells *in vitro*.<sup>93</sup> In an open trial of 32 patients with treatment refractory brain tumors, intravenous infusion of selenium (1000 mcg/day for 4-8 weeks) was associated with a slight to definite improvement in all participants. Symptomatic decrease was seen in nausea, emesis, headache, vertigo, and seizure activity. Although the results are largely credited to the selenium treatment, it should be noted these patients were concurrently receiving chemotherapy, oxygen therapy, vitamins E and A, dietary changes, and psychotherapy.<sup>94</sup> Unpublished research from the 1950s outlines the treatment of over 1000 malignancies with selenium compounds, reportedly with beneficial results.<sup>95</sup> Unfortunately, a study of this magnitude has yet to appear in the peer-reviewed literature.

## Selenium with Radiation

Little is known about the interaction between selenium supplementation and radiotherapy. In the one human trial available, patients with advanced rectal cancer were given daily supplementation with 400 mcg of selenium after treatment. The selenium was well-tolerated, but the researchers presented no data regarding interaction between the two treatments.<sup>96</sup> An animal study suggests that selenium depletion reduces the lethal dose of radiation.<sup>97</sup> Until more is known regarding the effect of selenium on radiotherapy, pharmacological doses (above 400 mcg/day) cannot be advised.

## Selenium with Chemotherapy

Interactions between selenium and platinum-containing chemotherapy agents have been extensively studied. In a mouse study, selenium decreased nephrotoxicity of cisplatin, while simultaneously increasing its anti-tumor activity.<sup>15</sup> Other animal studies confirmed these findings.<sup>16,98</sup> A randomized crossover trial in humans looked at the effect of selenium (4000 mcg/day from four days before until four days post-chemotherapy) on the toxicity of cisplatin. Selenium consumption was associated with a higher WBC count, even with less consumption of granulocyte stimulating factor. Nephrotoxicity, measured by urine enzymes, was also significantly less in patients taking selenium. No mention is made in this study of any effect of selenium intake on the therapeutic activity of cisplatin.<sup>99</sup>

One *in vitro* study suggests a selenium-containing antioxidant compound called Ebselen (2-phenyl-1,3-benzisoxazol-3(2H)one) has a mild inhibitory effect on the

## SELENIUM SUMMARY

- ◆ Data are incomplete regarding interaction between selenium and radiotherapy.
- ◆ Selenium increased the activity of cisplatin in mice, and decreased its toxicity in humans.
- ◆ No *in vivo* evidence exists to suggest that selenium reduces the effect of chemotherapy.

anti-tumor effect of bleomycin. The authors did not speculate on whether dietary selenium would have an adverse effect on therapeutic use of bleomycin.<sup>100</sup> Perhaps until these results are followed up, it would be best to avoid this combination.

## Coenzyme Q10 as Cancer Treatment

A series of case reports from the Institute for Biomedical Research at the University of Texas at Austin describe the therapeutic benefit of coenzyme Q10 (CoQ10) in cancer patients. These investigators have noted tumor regressions and long-term survival associated with oral CoQ10, at doses from 90 to 390 mg/day.<sup>101,102</sup> This same group used 90 mg CoQ10/day, combined with other antioxidants (vitamin C 2850 mg, vitamin E 2500 IU, b-carotene 32.5 IU, selenium 387 mcg) and 3.5 g omega-3 fatty acids, in an open trial in node-positive breast cancer patients. Patients also underwent conventional treatment. The investigators observed no distant metastasis in any patient, and partial remission in six of 32 patients. No patients died during the 18-month study period. The lack of a control group makes these data hard to interpret.<sup>103</sup>

## CoQ10 with Radiation

A 1998 study warns that CoQ10 reduces the effect of radiotherapy on small-cell lung cancer in mice. This trial did indeed show a significant inhibition of radiation-induced cell growth delay at 40 mg/kg oral dose, and a borderline inhibition at 20 mg/kg. However, no inhibitory effect on radiotherapy was noted

## CoQ10 SUMMARY

- ◆ Doses of CoQ10 commonly used in humans do not appear to inhibit the effect of radiotherapy *in vivo*.
- ◆ CoQ10 has been shown not to inhibit the effect of doxorubicin *in vivo*.
- ◆ No *in vivo* evidence suggests CoQ10 inhibits the effect of chemotherapy.

at 10 mg/kg CoQ10, a dose roughly equivalent to 700 mg in an adult human.<sup>104</sup> Based on this, the normal human dose of CoQ10 of 100-400 mg/day probably has little inhibitory effect on concurrent radiotherapy.

proliferation.<sup>8</sup> Impaired p53 expression is associated with many human cancers.<sup>109</sup> Melatonin is also known to modify many cytokines, including TNF, IL1, IL-2, IL-6, and gamma-inter-

### CoQ10 with Chemotherapy

A number of studies have looked at the capacity of CoQ10 to prevent the cardiac toxicity associated with doxorubicin. A small study in humans showed CoQ10 administration at 1 mg/kg led to an over 20-percent reduction in episodes of ECG change post-treatment compared with doxorubicin alone. Diarrhea and stomatitis were also significantly reduced.<sup>105</sup> A mouse study confirms the protective effect of CoQ10 treatment on the toxicity of doxorubicin. In this study, it was noted that CoQ10 did not reduce the anti-tumor effect of doxorubicin. Instead, a trend toward better tumor control was seen.<sup>106</sup> In a study of 20 leukemia patients undergoing treatment with the similar agent daunorubicin, 100 mg CoQ10 twice daily was able to significantly reduce adverse cardiac events as measured by echocardiography. No mention was made of the effect of CoQ10 treatment on the therapeutic benefit of daunorubicin chemotherapy.<sup>107</sup>

### Melatonin as Cancer Treatment

Although it is not usually considered a standard antioxidant, melatonin, the hormone secreted by the pineal gland in response to cycles of light and dark, has exhibited potent free radical-scavenging properties against hydroxyl and peroxy radicals.<sup>108</sup>

Melatonin has also been found to have some interesting anti-tumor properties *in vitro*. It increases p53 expression in breast cancer cells, and therefore significantly reduces cell

proliferation, in ways consistent with increased host defense against cancers.<sup>110</sup> Melatonin, perhaps through reduction of TNF secretion, has been shown to reduce cachexia in patients with metastatic solid tumors. Patients taking melatonin (20 mg/day) were found to have significantly less weight loss (3 kg vs. 16 kg) and disease progression (53% vs. 90%) than those treated with supportive care alone.<sup>111</sup>

In another study, 63 patients with non-small cell lung cancer refractory to cisplatin therapy were randomized to receive either 10 mg/day of melatonin or supportive care alone. Patients receiving melatonin lived longer on average than those receiving supportive care alone (6 vs. 3 months) and were more likely to survive for one year (8/31 survivors vs. 2/32). No drug-related toxicity was noted by the authors.<sup>112</sup> Treatment with melatonin (20 mg/day) was also associated with greater one-year survival than supportive care alone in patients with brain metastases.<sup>113</sup> Other studies have noted increased survival in malignant melanoma<sup>114</sup> and patients with metastatic disease.<sup>115</sup> The latter study stressed that based in its effects on the immune system, melatonin could be tested in association with other anti-tumor treatments.<sup>115</sup> The DiBella multitherapy of cancer, of which melatonin is a part (along with many other agents), was found not to have sufficient efficacy against advanced cancer to warrant further investigation.<sup>116</sup> Animal experiments suggest doses as high as 250 mg/kg are non-toxic.<sup>117</sup>

## Melatonin with Radiation

In a randomized trial including 30 patients with glioblastoma, the effect of radiotherapy plus 20 mg/day of melatonin was compared to that of radiotherapy alone. At the end of one year, six of the 14 patients receiving melatonin were still living, compared to one of the 16 undergoing radiotherapy alone. The authors also noted fewer side effects from radiotherapy in patients taking melatonin.<sup>118</sup>

## Melatonin with Chemotherapy

Melatonin has been studied a number of times as an adjunct to standard chemotherapy in humans. A phase II study used tamoxifen plus melatonin (20 mg/day) in the treatment of metastatic breast cancer which had progressed under treatment with tamoxifen alone. Four of the 14 patients tested had partial response to this combination, with a median of eight months before disease progression. Treatment was well-tolerated and relief of anxiety or depression was noted by many patients.<sup>19</sup> A similar study was conducted using the same combination of treatments in patients with metastatic solid tumors other than breast cancer which had not responded to previous chemotherapies. Partial response or stable disease was seen in 16/25 patients. One year survival was seen in 7/25 patients.<sup>119</sup>

In another phase II study, melatonin (20 mg/day) led to a normalization of platelet counts in nine of twelve breast cancer patients who acquired thrombocytopenia during epirubicin therapy. Objective tumor regression

## MELATONIN SUMMARY

- ◆ Melatonin increases tumor cell apoptosis.
- ◆ Melatonin decreases cachexia symptoms in humans.
- ◆ Melatonin improves survival time as sole agent in terminal cancer patients.
- ◆ Melatonin increases radiation effect in humans.
- ◆ Melatonin increases survival time and tumor response in patients treated with tamoxifen, cisplatin, and etoposide.
- ◆ No *in vivo* evidence suggests that melatonin decreases chemotherapy effect.

was noted in five of the 12 patients.<sup>120</sup> A randomized trial investigated the difference between melatonin (20 mg/day), cisplatin, and etoposide, and treatment with cisplatin and etoposide alone in advanced non-small cell lung cancer. One-year survival was significantly higher in patients receiving adjunctive melatonin compared to standard chemotherapy alone (15 of 34 vs. 7 of 36). There was a non-significant trend toward greater tumor response in melatonin-treated patients as well (11 of 34 vs. 6 of 36). Myelosuppression, neuropathy, and cachexia were noted less frequently in patients receiving melatonin than in those that were receiving only chemotherapy.<sup>121</sup> A double-blind trial was unable to replicate this protective effect of melatonin on the myelosuppression mediated by carboplatin and etoposide. This may reflect the effect higher doses of chemotherapeutic agents given in the second trial. The authors concluded that potentiation of the effect of chemotherapy by melatonin was unlikely.<sup>122</sup> Concomitant therapy with melatonin (40 mg/day) has been found to increase the effect of interleukin-2 against a variety of solid cancers.<sup>123</sup> The combination of melatonin (40 mg/day) and interleukin-2 has been found to be a more effective treatment than cisplatin and etoposide in non-small cell lung cancer.<sup>124</sup>

## N-acetylcysteine as Cancer Treatment

We were unable to locate research demonstrating N-acetylcysteine (NAC) as an anti-tumor agent. NAC is known to be safe in doses well above that used in most human trials. Diarrhea is the most commonly reported side effect of higher doses.<sup>125</sup>

## N-acetylcysteine with Radiation

The effect of NAC on radiotherapy was observed in 10 patients with non-small cell lung cancer. NAC was administered by IV (100 mg/kg over 30 minutes) before the first radiation session, followed by 30 mg/kg IV over the next seven hours. They then inhaled a nebulized solution containing 600 mg NAC 30 minutes prior to and after each subsequent radiation treatment. Patients receiving NAC had tissue reactions and tumor responses from radiotherapy judged to be similar to a control group. Average survival time was similar between patients receiving NAC treatment and those who underwent radiation only. The authors concluded the treatment outcome did not justify the expense.<sup>126</sup> An *in vitro* experiment showed that NAC is not likely to block the tumor cell killing effect of radiation.<sup>127</sup>

Application of gauze soaked in 10-percent NAC solution to the skin 15 minutes before radiotherapy was tested in an unblinded trial. Topical NAC appeared to be associated with more rapid healing and less use of analgesics compared with those in the control group.<sup>128</sup>

## N-acetylcysteine with Chemotherapy

NAC has been employed with a number of chemotherapy agents as a means of reducing toxicity. It has gained such recognition in this regard that it is often used in clinical trials as an adjunct to the therapy being tested.

Animal studies have shown NAC protects against hematuria resulting from cyclophosphamide therapy without reducing its tumoricidal effect.<sup>129-131</sup> A phase I human trial found 6 g/day NAC completely protected against hematuria, which is a dose-limiting side effect of ifosfamide (an analogue of cyclophosphamide).<sup>132</sup> Another human study found similar results.<sup>133</sup>

Human trials with dosages as high as 140 mg/kg NAC were unable to show any prevention of cardiomyopathy due to treatment with doxorubicin. One of these trials also noted that NAC treatment was not associated with a reduction of the anti-tumor action of doxorubicin,<sup>134,135</sup> and a mouse study concurred. This study also noted prevention of cardiotoxicity, which as noted above, was not replicated in human studies.<sup>136</sup> Another animal study raises the possibility of a reduction of the anti-neoplastic action of doxorubicin by NAC. NAC did, however, lead to a significant reduction in cardiac toxicity.<sup>137</sup> As data on the subject of doxorubicin with NAC are currently conflicting, this combination might best be avoided at this time.

### N-ACETYLCYSTEINE SUMMARY

- ◆ NAC does not appear to block the therapeutic effect of radiation in humans or *in vitro*.
- ◆ NAC does not block the therapeutic effect of cyclophosphamide *in vivo*.
- ◆ NAC appears to be associated with limited benefit in cancer therapy.
- ◆ *One of two animal studies shows NAC to reduce the efficacy of doxorubicin. This finding was not replicated in human studies.*
- ◆ *NAC has been shown in vitro to reduce the efficacy of cisplatin.*

It has been shown in two separate *in vitro* studies that NAC inhibits the cytotoxic activity of cisplatin.<sup>138,139</sup> NAC may have a role, however, in the reversal of renal toxicity due to cisplatin.<sup>140</sup> Other than use in salvage therapy, the combination of cisplatin and NAC should also probably be avoided at this time.

### Glutathione as Cancer Treatment

Glutathione is a tri-peptide thiol (sulfhydryl-containing) compound which is the major intracellular antioxidant in the body. A human study suggests oral glutathione is poorly absorbed, with negligible plasma concentrations found after administration of a single 3 g oral dose.<sup>141</sup> This conclusion is contradicted by a rat study which found dietary glutathione was absorbed in a dose-dependent manner, and remained elevated in the plasma for three hours after administration.<sup>142</sup> Aerosol administration of glutathione is an effective means of delivery to the plasma<sup>143</sup>, as is intravenous administration.<sup>144</sup> Glutathione is thought to be non-toxic to humans,<sup>144</sup> although one study found a 5 g oral daily dose was associated with GI irritation and sulfur odor.<sup>145</sup>

A case report from Japan in 1984 raised the possibility that glutathione might be an effective treatment for hepatocellular carcinoma. A trial of six hepatocarcinoma patients on 5 g oral glutathione daily found regression or stagnation of tumor growth in three patients. One patient also had a reduction in alpha-fetoprotein (a tumor marker) from 496 to 5. Two patients of the six survived for one year. These patients were both women, raising the possibility of a sex-dependent effect.<sup>145</sup> In a rat study, oral administration of glutathione caused regression of liver tumors, and increased survival of tumor-bearing animals.<sup>146</sup> The usefulness of glutathione as an anti-tumor agent may be limited to the liver, kidney, and peripheral neurons, as these are the only tissues believed to have sufficient transport enzymes for cellular uptake.<sup>144</sup> For further discussion

of glutathione as an antioxidant, refer to the review article by Kidd.<sup>147</sup>

### Glutathione with Radiation

A randomized pilot trial with 45 participants investigated the radioprotective effect of glutathione. Patients were administered 1200 mg glutathione or saline placebo intravenously 15 minutes prior to pelvic radiotherapy. Patients receiving glutathione suffered less from post-therapy diarrhea (28%, compared to 52% of controls) and were more likely to complete the treatment cycle (71% to 52%). Although the sample size was too small to show significance, the authors concluded glutathione was unlikely to interfere with the effect of radiation on neoplasms.<sup>148</sup> The argument was not based on patient outcome.

### Glutathione with Chemotherapy

Increased cellular concentrations of glutathione have been associated with resistance to both anthracyclines and platinum agents.<sup>149</sup> Given the suggestion of the inability of most cell types to take up exogenous glutathione,<sup>144</sup> decreased chemotherapy efficacy due to glutathione administration may be limited to liver, kidney, and neurological tumors.

The use of cisplatin and glutathione concurrently has been studied in several small human trials. One human trial found 3 g/m<sup>2</sup> intravenous glutathione given 20 minutes prior to cisplatin (100 mg/m<sup>2</sup>) led to a significant reduction in nephrotoxicity in patients with ovarian cancer compared with those receiving cisplatin alone. There was a trend toward greater tumor response in the glutathione group—73 percent, compared to 62 percent in the control group.<sup>150</sup> A similar trial using smaller doses of glutathione (2500 mg/m<sup>2</sup>) and cisplatin (50 - 75 mg/m<sup>2</sup>) did not find the reduction in nephrotoxicity reported above. However, the trend toward greater tumor response with glutathione treatment (72%

## GLUTATHIONE SUMMARY

- ◆ Glutathione is not thought to interfere with radiotherapy.
- ◆ Glutathione decreases toxicity, and appears to increase the anti-tumor effect, of cisplatin in humans.
- ◆ Glutathione/chemotherapy interactions are poorly explored.

response, compared to 52% in controls) was comparable.<sup>151</sup>

A double-blind trial studied the neuroprotective effect of intravenous glutathione (1500 mg/m<sup>2</sup>) during cisplatin treatment for gastric cancer. After nine weeks, no patient of the 24 receiving glutathione, but 16 of 18 patients receiving placebo, had developed neuropathy symptoms. Again, a trend toward greater tumor response (76%, compared to 52% in controls) was seen with glutathione treatment.<sup>152</sup>

An open trial with 79 ovarian cancer patients found i.v. administration of 2500 mg glutathione prior to treatment with a cisplatin / cyclophosphamide combination led to greater tumor response and reduced toxicity compared to that found in other trials using these chemotherapeutic agents.<sup>153</sup> Another trial using the same glutathione dose with the same combination chemotherapy found no cases of nephrotoxicity in 20 patients. The authors reported, based on their experience, that the effect of the chemotherapy was not interfered with, and may have been enhanced.<sup>154</sup> These results have not been followed up in controlled trials, however. The interactions between glutathione and chemotherapy agents other than cisplatin and cyclophosphamide have not been explored in human trials.

### Flavonoids as Cancer Treatment

Flavonoids are plant compounds known to have antioxidant properties *in vitro* and *in vivo*. Many of the thousands of flavonoids in nature have been studied for anti-cancer properties. Space does not permit a detailed discussion of this work. The most well characterized anti-tumor flavonoids are epigallocatechin gallate (from green tea),<sup>155</sup> genistein (from soy and red clover),<sup>156,157</sup>

curcumin (from turmeric),<sup>158</sup> silibinin (from milk thistle),<sup>159</sup> and quercetin (from many yellow vegetables).

The authors are presently preparing a review of the use of quercetin as cancer therapy.

### Flavonoids with Radiation

Little is known about the effects of flavonoids on radiotherapy. An *in vitro* experiment showed post-treatment application of quercetin caused greater cell death in radiation-treated hepatoma cells than radiation alone. In the same experiment, genistein was shown to be associated with increased cell death from radiation when applied during or after treatment.<sup>160</sup> Many different rutosides (flavonoids with similar structures to quercetin) were found to have neither a protective nor sensitizing effect on radiotherapy in experimental mouse tumors.<sup>161</sup> There is not enough evidence currently to support or argue against the use of therapeutic doses of flavonoids together with radiation.

### Flavonoids with Chemotherapy

Recent research has focused on the ability of flavonoids to increase the concentration of chemotherapeutics in tumor cells. Resistance to many chemotherapy agents is thought to be due to reduced accumulation in tumor cells.<sup>162</sup> Oral administration of green tea in mice to increased the concentration of doxorubicin in two tumor types, but not in normal tissue. The anti-tumor activity of doxorubicin was enhanced 2.5 times.<sup>163</sup> Another report confirmed this action of green tea, finding the tumor inhibition of doxorubicin increased from negligible to 62 percent. This report, however, determined the activity of green tea to be due

## FLAVONOID SUMMARY

- ◆ Several flavonoids increase radiosensitivity of tumor cells *in vitro*.
- ◆ Green tea, quercetin, and genistein increase the concentration of chemotherapy agents in some resistant cell lines.
- ◆ Quercetin increases the anti-tumor activity of cisplatin and busulfan *in vivo*, and does not interfere with the activity of doxorubicin or etoposide.
- ◆ *Tamoxifen activity has been reduced in vivo by tangeretin and in vitro by genistein.*

to an amino acid, theanine, rather than its flavonoid content.<sup>164</sup>

Quercetin has been shown *in vitro* to increase the concentration of doxorubicin in multidrug-resistant human breast cancer cells.<sup>165</sup> Conversely, quercetin decreased the concentration of doxorubicin in a resistant human colon cancer cell line.<sup>166</sup> Quercetin and genistein both increased the concentration of daunorubicin in some multidrug-resistant cell lines, but had no effect in others.<sup>167</sup> Genistein *in vitro* increased the concentration of cisplatin in resistant cell lines.<sup>168</sup> Other than the green tea studies, none of these studies analyzed cell death due to flavonoid administration.

In mice with transplanted human tumors, quercetin (20 mg/kg) given with cisplatin reduced tumor growth to a greater degree than cisplatin alone.<sup>169</sup> In a separate experiment, quercetin enhanced the effect of cisplatin and busulfan *in vitro* and *in vivo*. No enhancement or reduction of the anti-tumor activity of doxorubicin or etoposide was seen.<sup>170</sup> An *in vitro* study found quercetin increased the effect of doxorubicin against resistant breast cancer cells.<sup>165</sup>

It should be cautioned, however, that a recent study showed a potential adverse interaction. Tangeretin, a flavonoid found in citrus fruits, completely blocked the inhibitory effect of tamoxifen on mammary cancer in mice.<sup>171</sup> One *in vitro* study suggests attenuation

of tamoxifen may be a concern with genistein as well.<sup>172</sup> Another *in vitro* study, however, shows tamoxifen and genistein synergistically inhibit the growth of estrogen receptor-negative breast cancer cells.<sup>173</sup> Until the flavonoid-tamoxifen interactions are investigated more completely, it may be best to avoid using therapeutic doses of flavonoid compounds in breast cancer treated with tamoxifen.

## Combinations of Antioxidants

Given that many antioxidants have been shown to have anti-tumor properties, it is worth exploring their use in combination. A study in mice found co-administration of beta-carotene and alpha-tocopherol led to much greater tumor regression than either agent alone. The effect was synergistic, being much greater than the sum of the mild tumor inhibition of beta-carotene and alpha-tocopherol.<sup>174</sup> Other studies have shown multivitamin supplements were associated with fewer recurrences of solid tumors after remission following standard oncologic therapies.<sup>20,21</sup>

A small double-blind trial of a mixture of antioxidants, including 600 mg vitamin E, 1 g vitamin C, and 200 mg NAC taken only during treatment, looked at the potential of this mixture to prevent cardiotoxicity during chemo- and radiotherapy. No patient taking the antioxidant mixture had a fall in ejection fraction greater than 10 percent. In patients taking placebo, four of six patients undergoing radiotherapy and two of seven patients treated with chemotherapy had an ejection fraction reduction of 10 percent or more. Treatment outcomes in patients taking antioxidants versus placebo were not discussed.<sup>175</sup>

An open trial of combination antioxidant treatment along with chemotherapy and radiation in patients with small-cell lung cancer had encouraging results. Patients taking the supplement, which contained at least 15,000 IU vitamin A, 10,000 IU beta-carotene, 300



## COMBINATION ANTIOXIDANT SUMMARY

- ◆ Combinations of antioxidants have been shown to have synergistic anti-tumor effects *in vivo*.
- ◆ Combinations of antioxidants with chemotherapy and radiation have been shown to increase survival time and reduce toxicity in humans.

IU alpha-tocopherol, 2 g vitamin C, and 800 mcg selenium, were able to tolerate chemotherapy and radiation well. Their two-year survival rate was greater than that of historical controls (>33% to <15%), with 44 percent still alive at the end of the study (mean survival time for survivors = 32 months). No side effects from nutritional treatment were noted.<sup>17</sup> Hopefully these promising results will be followed up with larger and more well-controlled studies.

### Current Attitudes and New Approaches to Treatment

Cancer therapy has been remarkably consistent for the last 50 years. Surgery, radiation, and chemotherapy have been the cornerstones of conventional treatment. Not surprisingly, the clinical success of these treatments has reached a plateau.<sup>176</sup> Some authors have even questioned the validity of chemotherapy as a treatment for most cancers.<sup>177</sup> Clearly, there is a need for new therapies which can increase the efficacy of cancer treatment. Careful application of antioxidants may be a means helping to raise cancer therapy to a new level of success.<sup>4</sup>

The attitude of many conventional practitioners toward antioxidant therapy for cancer has been hostile.<sup>178</sup> Others have raised the argument that antioxidants could blunt the effect of standard therapies, particularly alkylating, platinum, and tumor antibiotic agents, which are oxidative in nature.<sup>5</sup> While this appears a theoretical concern, the evidence reviewed here shows that this proposed interaction of anti- and pro-oxidant therapies is not generally of primary importance *in vivo*. It is time to put this argument in perspective.

### Potential Mechanisms of Antioxidants in Cancer Therapy

How could antioxidant therapy protect normal cells against damage from cancer therapies, while often increasing their cytotoxic effect against

malignant cells? While the answer to this question is not entirely mapped out, there are concepts which might help us understand. One is the recent evidence that radiation and chemotherapy often harm DNA to a relatively minor extent, which causes the cells to undergo apoptosis, rather than necrosis.<sup>6</sup> Since many antioxidant treatments stimulate apoptotic pathways,<sup>7,8</sup> the potential exists for a synergistic effect with radiation or chemotherapy with antioxidants.

A second concept is that the defensive mechanisms of many cancer cells are known to be impaired. This presumably makes tumor cells unable to use the extra antioxidants in a repair capacity; this has been illustrated *in vitro*. An experimental murine ascites tumor cell line was found to have 10 -100 times less catalase than comparable normal cells. This led to a build-up of hydrogen peroxide in the cells upon treatment with vitamin C, in turn leading to cell death. The cytotoxic effects of vitamin C were completely eliminated by addition of catalase to the cell culture.<sup>179</sup> Since publication of these findings, most human tumor cell lines studied have proved to be similarly low in catalase.<sup>180</sup>

## Caveats When Considering Using Antioxidants in Cancer Treatment

We wish to emphasize three concerns regarding the use of antioxidants raised in this paper. One is the routine use of N-acetylcysteine with certain chemotherapeutic agents, namely cisplatin and doxorubicin. Given the limited therapeutic benefits associated with NAC in cancer treatment, and the number of other antioxidants shown above to help reduce the toxicities of these two chemotherapeutic agents, there appears little reason to consider NAC a first-line adjunct with either agent. Since the potential for adverse interaction with chemotherapy appears to be greater with NAC, perhaps it should be used only in situations where it has clearly been shown to not interfere with other therapies.

The second concern we wish to reiterate is the interaction between tangeretin and tamoxifen. Except in cases where interactions with specific flavonoids are clearly defined, it seems prudent to avoid treatment with flavonoids in therapeutic doses concurrently with tamoxifen. It is unknown currently if there is any reduction in tamoxifen activity associated with dietary flavonoids, which are ubiquitous in the plant kingdom.

The third area of concern is the potential reduction of 5-fluorouracil (5-FU) activity by beta-carotene.<sup>58</sup> The nature of this interaction is not clear. Until this is clarified, the combination would best be avoided.

## Conclusion

Frequently, the effects of using antioxidants concurrent with chemotherapy and radiation are synergistic. Except for three specific interactions outlined above (flavonoids with tamoxifen, NAC with doxorubicin, and beta-carotene with 5-fluorouracil), there is no evidence to date showing that natural antioxidants interfere with conventional cancer therapeutics *in vivo*. Studies have shown patients

treated with antioxidants, with or without chemotherapy and radiation, have many benefits. Patients have been noted to tolerate standard treatment better, experience less weight loss, have a better quality of life, and most importantly, live longer than patients receiving no supplements. It is time to research the role of these agents in conventional oncologic treatment, rather than dismiss them as a class based on theoretical concerns.

The authors wish to thank the Smiling Dog Foundation for financial support of this project and to Bastyr University for its administration.

## References

1. VandeCreek L, Rogers E, Lester J. Use of alternative therapies among breast cancer outpatients compared with the general population. *Altern Ther Health Med* 1999;5:71-76.
2. Singh DK, Lippman SM. Cancer chemoprevention part 1: retinoids and carotenoids and other classic antioxidants. *Oncology* 1998;12:1643-1660.
3. Prasad KN, Kumar A, Kochupillai V, Cole WC. High doses of multiple antioxidant vitamins: essential ingredients in improving the efficacy of standard cancer therapy. *J Am Coll Nutr* 1999;18:13-25.
4. Weijl NI, Cleton FJ, Osanto S. Free radicals and antioxidants in chemotherapy induced toxicity. *Cancer Treat Rev* 1997;23:209-240.
5. Labriola D, Livingston R. Possible interactions between dietary antioxidants and chemotherapy. *Oncology* 1999;13:1003-1012.
6. Schmitt CA, Lowe SW. Apoptosis and therapy. *J Pathol* 1999;187:127-137.
7. Chinery R, Brockman JA, Peeler MO, et al. Antioxidants enhance the cytotoxicity of chemotherapeutic agents in colorectal cancer: a p53-independent induction of p21 via C/EBP-beta. *Nat Med* 1997;3:1233-1241.
8. Mediavilla MD, Cos S, Sanchez-Barcelo EJ. Melatonin increases p53 and p21WAF1 expression in MCF-7 human breast cancer cells *in vitro*. *Life Sci* 1999;65:415-420.

9. Seifter E, Rettura G, Padawer J. Vitamin A and beta-carotene as adjunctive therapy to tumour excision, radiation therapy and chemotherapy. In Prasad K, ed. *Vitamins Nutrition and Cancer*. New York: Karger Press; 1984:2-19.
10. Thatcher N, Blackledge G, Crowther D. Advanced recurrent squamous cell carcinoma of the head and neck. *Cancer* 1980;46:1324-1328.
11. Shimpo K, Nagatsu T, Yamada K, et al. Ascorbic acid and adriamycin toxicity. *Am J Clin Nutr* 1991;54:1298S-1301S.
12. Taper HS, de Gerlache J, Lans M, et al. Non-toxic potentiation of cancer chemotherapy by combined C and K3 vitamin pre-treatment. *Int J Cancer* 1987;40:575-579.
13. Sue K, Nakagawara A, Okuzono SI, et al. Combined effects of vitamin E (alpha-tocopherol) and cisplatin on the growth of murine neuroblastoma *in vivo*. *Eur J Cancer Clin Oncol* 1988;24:1751-1758.
14. Myers CE, McGuire WP, Liss RH, et al. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. *Science* 1977;197:165-167.
15. Naganuma A, Satoh M, Imura N. Effect of selenite on renal toxicity and antitumor activity of cis-diamminedichloroplatinum in mice inoculated with ehrlich ascites tumor cell. *J Pharm Dyn* 1984;7:217-220.
16. Berry JP, Pauwella C, Tlouzeau S, et al. Effect of selenium in combination with cis-diamminedichloroplatinum(II) in the treatment of murine fibrosarcoma. *Cancer Res* 1984;44:2864-2868.
17. Jaakkola K, Lahteenmaki P, Laakso J, et al. Treatment with antioxidant and other nutrients in combination with chemotherapy and irradiation in patients with small-cell lung cancer. *Anticancer Res* 1992;12:599-606.
18. Lissoni P, Paolorossi F, Ardizzoia A. A randomized study of chemotherapy with cisplatin plus etoposide versus chemoendocrine therapy with cisplatin, etoposide and the pineal hormone melatonin as a first-line treatment of advanced non-small cell lung cancer patients in a poor clinical state. *J Pineal Res* 1997;23:15-19.
19. Lissoni P, Barni S, Meregalli S, et al. Modulation of cancer endocrine therapy by melatonin: a phase II study on tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone. *Br J Cancer* 1995;71:854-856.
20. Whelan RL, Horvath KD, Gleason NR, et al. Vitamin and calcium supplement use is associated with decrease adenoma recurrence in patients with a previous history of neoplasia. *Dis Colon Rectum* 1999;42:212-217.
21. Lamm DL, Riggs DR, Shriver JS, et al. Megadose vitamins in bladder cancer: a double-blind clinical trial. *J Urol* 1994;151:21-26.
22. Yoshida M, Sakai T, Hosokawa N, et al. The effect of quercetin on cell cycle progression and growth of human gastric cancer cells. *FEBS Lett* 1990;260:10-13.
23. Holland JF, Bast RC, Morton DL, et al, eds. *Cancer Medicine*. 4<sup>th</sup> ed. Baltimore, MD: Williams and Wilkins; 1997.
24. Smith MA, Parkinson DR, Cheson BD, Friedman MA. Retinoids in cancer therapy. *J Clin Oncol* 1992;10:839-864.
25. Nikolaou AC, Fountazilas G, Daniilidis I. Treatment of unresectable recurrent head and neck carcinoma with 13-cis-retinoic acid and interferon-alpha. A phase II study. *J Laryngol Otol* 1996;110:857-861.
26. Chomienne C, Ballerini P, Balitrand N, et al. Retinoic acid therapy for promyelocytic leukemia. *Lancet* 1989;2:746-747.
27. Warrell RP, Frankel SR, Miller WH, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). *N Engl J Med* 1991;324:1385-1393.
28. Meng-er H, Yu-chen Y, Shu-rong C, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. *Blood* 1988;72:567-572.
29. Castaigne S, Chomienne C, Daniel MT, et al. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical Results. *Blood* 1990;76:1704-1709.
30. Breitman TR, Selonick SE, Collins SJ. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. *Proc Natl Acad Sci* 1980;77:2936-2940.
31. Meyskens FL, Graham V, Chvapil M, et al. A phase I trial of beta-all-trans-retinoic acid delivered via a collagen sponge and a cervical cap for mild or moderate intraepithelial cervical neoplasia. *J Natl Cancer Inst* 1983;71:921-925.

32. Meyskens FL, Surwit E, Moon TE, et al. Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: a randomized trial. *J Natl Cancer Inst* 1994;86:539-543.
33. Hong WK, Lippman SM, Itri LM, et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. *N Engl J Med* 1990;323:795-801.
34. Doyle LA, Giangiuolo D, Hussain A. Differentiation of human variant small cell lung cancer cell lines to a classic morphology by retinoic acid. *Cancer Res* 1989;49:6745-6751.
35. Pastorino U, Infante M, Maioli M, et al. Adjuvant treatment of stage I lung cancer with high-dose vitamin A. *J Clin Oncol* 1993;11:1216-1222.
36. Grunberg SM, Itri LM. Phase II study of isotretinoin in the treatment of advanced non-small cell lung cancer. *Cancer Treat Rep* 1987;71:1097-1098.
37. Meyskens FL, Tuthill RJ, Sondak VK, et al. Randomized trial of vitamin A versus observation as adjuvant therapy in high-risk primary malignant melanoma: a Southwest Oncology Group study. *J Clin Oncol* 1994;12:2060-2065.
38. Culine S, Kramar A, Droz JP, Theodore C. Phase II study of all-trans retinoic acid administered intermittently for hormone refractory prostate cancer. *J Urol* 1999;161:173-175.
39. Hennekens CH, Mayrent SL, Willett W. Vitamin A, carotenoids, and retinoids. *Cancer* 1986;58:1837-1841.
40. Murakoshi M, Takayasu J, Kimura O, et al. Inhibitory effects of alpha-carotene on proliferation of the human neuroblastoma cell line GOTO. *J Natl Cancer Inst* 1989;81:1649-1652.
41. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. *N Engl J Med* 1994;330:1029-1035.
42. Hennekens CH, Buring JE, Manson JE, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. *N Engl J Med* 1996;334:1145-1149.
43. Gann PH, Ma J, Giovannucci E, et al. Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis. *Cancer Res* 1999;59:1225-1230.
44. Amir H, Karas M, Giat J, et al. Lycopene and 1,25-dihydroxyvitamin D3 cooperate in the inhibition of cell cycle progression and induction of differentiation in HL-60 leukemic cells. *Nutr Cancer* 1999;33:105-112.
45. Levy J, Bosin E, Feldman B, et al. Lycopene is a more potent inhibitor of human cancer cell proliferation than either alpha-carotene or beta-carotene. *Nutr Cancer* 1995;24:257-266.
46. Duchesne GM, Hutchinson LK. Reversible changes in radiation response induced by all-trans retinoic acid. *Int J Radiat Oncol Biol Phys* 1995;33:875-880.
47. Park TK, Lee JP, Kim SN, et al. Interferon-alpha 2a, 13-cis-retinoic acid and radiotherapy for locally advanced carcinoma of the cervix: a pilot study. *Eur J Gynaecol Oncol* 1998;19:35-38.
48. Tannock IF, Suit HD, Marshall N. Vitamin A and the radiation response of experimental tumors: an immune mediated effect. *J Natl Cancer Inst* 1972;48:731-741.
49. Mills EED. The modifying effect of beta-carotene on radiation and chemotherapy induced oral mucositis. *Br J Cancer* 1988;57:416-417.
50. Kennedy AR, Krinsky NI. Effects of retinoids, beta-carotene, and canthaxanthin on UV- and X-ray induced transformation of C3H10T1/2 cells *in vitro*. *Nutr Cancer* 1994;22:219-232.
51. Doyle LA, Giangiuolo D, Hussain A. Differentiation of human variant small cell lung cancer cell lines to a classic morphology by retinoic acid. *Cancer Res* 1989;49:6745-6751.
52. Adwankar M, Banerji A, Ghosh S. Differential response of retinoic acid pretreated human synovial sarcoma cell line to anticancer drugs. *Tumori* 1991;77:391-394.
53. Nagai Y, Horie T, Awazu S. Vitamin A, a useful biochemical modulator capable of preventing intestinal damage during methotrexate treatment. *Pharmacol Toxicol* 1993;73:69-74.
54. Weisman RA, Christen R, Los G, et al. Phase I trial of retinoic acid and cis-platinum for advanced squamous cell cancer of the head and neck based on experimental evidence of drug synergism. *Otolaryngol Head Neck Surg* 1998;118:597-602.

55. Kalemkerian GP, Jiroutek M, Ettinger DS, et al. A phase II study of all-trans-retinoic acid plus cisplatin and etoposide in patients with extensive stage small cell lung carcinoma. *Cancer* 1998;83:1102-1108.
56. Recchia F, Sica G, Casucci D, et al. Advanced carcinoma of the pancreas: phase II study of combined chemotherapy, beta-interferon, and retinoids. *Am J Clin Oncol* 1998;21:275-278.
57. Tsutani H, Ueda T, Uchida M, Nakamura T. Pharmacological studies of retinol palmitate and its clinical effect in patients with acute non-lymphocytic leukemia. *Leukemia Res* 1991;15:463-471.
58. Teicher BA, Schwartz JL, Holden SA, et al. *In vivo* modulation of several anticancer agents by beta-carotene. *Cancer Chemother Pharmacol* 1994;34:235-241.
59. Cameron E, Pauling L. Supplemental ascorbate in the supportive treatment of cancer: prolongation of survival times in terminal human cancer. *Proc Natl Acad Sci* 1976;73:3685-3689.
60. Cameron E. Protocol for the use of vitamin C in the treatment of cancer. *Med Hypothesis* 1991;36:190-194.
61. Creagan ET, Moertel CG, O'Fallon JR, et al. Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer: a controlled trial. *N Engl J Med* 1979;301:687-690.
62. Moertel CG, Fleming TR, Creagan ET, et al. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. *N Engl J Med* 1985;312:137-141.
63. Riordan HD, Jackson JA, Riordan NH, Schultz M. High-dose intravenous vitamin C in the treatment of a patient with renal cell carcinoma of the kidney. *J Orthomol Med* 1998;13:72-73.
64. Riordan NH, Riordan HD, Meng X, et al. Intravenous ascorbate as a tumor cytotoxic chemotherapeutic agent. *Med Hypotheses* 1995;44:207-213.
65. Rivers JM. Safety of high-level vitamin C ingestion. *Ann NY Acad Sci* 1988;498:445-454.
66. Cameron E, Campbell A. The orthomolecular treatment of cancer. II. Clinical trial of high-dose ascorbic acid supplements in advanced human cancer. *Chem Biol Interactions* 1974;9:285-315.
67. Kakar SC, Wilson CWM, Moriarty MJ. The relationship between cancer, radiotherapy and vitamin C. *Ir J Med Sci* 1977;146:289-294.
68. Taper HS, Keyeux A, Roberfroid M. Potentiation of radiotherapy by nontoxic pretreatment with combined vitamins C and K3 in mice bearing solid transplantable tumor. *Anticancer Res* 1996;16:499-504.
69. Okunieff P. Interactions between ascorbic acid and the radiation of bone marrow, skin, and tumor. *Am J Clin Nutr* 1991;54:1281S-1283S.
70. Okunieff P, Suit HD. Toxicity, radiation sensitivity modification, and combined drug effects of ascorbic acid with misonidazole *in vivo* on FSall murine fibrosarcomas. *J Natl Cancer Inst* 1987;79:377-381.
71. Tewfik FA, Tewfik HH, Riley EF. The influence of ascorbic acid on the growth of solid tumors in mice and on tumor control by X-irradiation. *Int J Vitam Nutr Res Suppl* 1982;23:257-263.
72. Hanck AB. Vitamin C and cancer. *Prog Clin Biol Res* 1988;259:307-320.
73. Halperin EC, Gaspar L, George S, et al. A double-blind, randomized, prospective trial to evaluate topical vitamin C solution for the prevention of radiation dermatitis. *Int J Rad Oncol Biol Phys* 1993;26:413-416.
74. Wells WW, Rocque PA, Xu DP. Ascorbic acid and cell survival of adriamycin resistant and sensitive MCF-7 breast tumor cells. *Free Rad Biol Med* 1995;18:699-708.
75. Kurbacher CM, Wagner U, Kolster B, et al. Ascorbic acid (vitamin C) improves the antineoplastic activity of doxorubicin, cisplatin, and paclitaxel in human breast carcinoma cells *in vitro*. *Cancer Lett* 1996;103:183-189.
76. Chiang CD, Song EJ, Yang VC, Chao CCK. Ascorbic acid increases drug accumulation and reverses vincristine resistance of human non-small-cell lung-cancer cells. *Biochem J* 1994;301:759-764.
77. Turley JM, Funakoshi S, Ruscetti FW, et al. Growth inhibition and apoptosis of RL human B lymphoma cells by vitamin E succinate and retinoic acid: role for transforming growth factor beta. *Cell Growth Differ* 1995;6:655-663.
78. Turley JM, Fu TF, Ruscetti FW, et al. Vitamin E succinate induces Fas-mediated apoptosis in estrogen receptor-negative human breast cancer cells. *Cancer Res* 1997;57:881-890.

79. Elattar TMA, Virji AS. Biphasic action of vitamin E on the growth of human oral squamous carcinoma cells. *Anticancer Res* 1999;19:365-368.
80. Helson L. A phase I study of vitamin E and neuroblasoma. In: Prasad ed. *Vitamins, Nutrition, and Cancer*. New York: Karger Press; 1984:274-281.
81. Gogos CA, Ginopoulos P, Salsa B, et al. Dietary omega-3 polyunsaturated fatty acids plus vitamin E restore immunodeficiency and prolong survival for severely ill patients with generalized malignancy. *Cancer* 1998;82:395-402.
82. Kelloff GJ, Crowell JA, Boone CW. Clinical development plan: vitamin E. *J Cell Biochem Suppl* 1994;20:282-299.
83. Bendich A, Machlin LJ. Safety of oral intake of vitamin E. *Am J Clin Nutr* 1988;48:612-619.
84. Sakamoto K, Sakka M. Reduced effect of irradiation on normal and malignant cells irradiated *in vivo* in mice pretreated with vitamin E. *Br J Radiology* 1973;46:538-540.
85. Fonck K, Konings AWT. The effect of vitamin E on cellular survival after X irradiation of lymphoma cells. *Br J Radiology* 1978;51:832-833.
86. Kagreud A, Peterson HI. Tocopherol in irradiation of experimental neoplasms. *Acta Radiol Oncol* 1981;20:97-100.
87. Delanian S. Striking regression of radiation-induced fibrosis by a combination of pentoxifylline and tocopherol. *Br J Radiology* 1998;71:892-894.
88. Sonneveld P. Effect of alpha-tocopherol on the cardiotoxicity of adriamycin in the rat. *Cancer Treat Rep* 1978;62:1033-1036.
89. Perez Ripoll EA, Rama BN, Webber MM. Vitamin E enhances the chemotherapeutic effects of adriamycin on human prostatic carcinoma cells *in vitro*. *J Urol* 1986;136:529-531.
90. Sue K, Nakagawara A, Okuzono SI, et al. Combined effects of vitamin E (alpha-tocopherol) and cisplatin on the growth of murine neuroblastoma *in vivo*. *Eur J Cancer Clin Oncol* 1988;24:1751-1758.
91. von Oefele F. Some remarks on the treatment of cancerous growths with selenium compounds. *American Medicine* 1912;18:216-219.
92. Watrach AM, Milner JA, Watrach MA. Effect of selenium on growth rate of canine mammary carcinoma cells in athymic nude mice. *Cancer Lett* 1982;15:137-143.
93. Watrach AM, Milner JA, Watrach MA, Poirier KA. Inhibition of human breast cancer cells by selenium. *Cancer Lett* 1984;25:41-47.
94. Pakdaman A. Symptomatic treatment of brain tumor patients with sodium selenite, oxygen, and other supportive measures. *Biol Trace Elem Res* 1998;62:1-6.
95. Ladas HS. The potential of selenium in the treatment of cancer. *Holistic Med* 1989;4:145-156.
96. Hehr T, Hoffmann W, Bamberg M. Role of sodium selenite as an adjuvant in radiotherapy of rectal carcinoma. *Med Klin* 1997;92:S48-S49.
97. Myers C, Katki A, Travis E. Effect of tocopherol and selenium on defenses against reactive oxygen species and their effect on radiation sensitivity. *Ann NY Acad Sci* 1982;393:419-425.
98. Ohkawa K, Tsukada Y, Dohzono H, et al. The effects of co-administration of selenium and cis-platin (CDDP) on CDDP-induced toxicity and antitumor activity. *Br J Cancer* 1988;58:38-41.
99. Hu YJ, Chen Y, Zhang YQ, et al. The protective role of selenium on the toxicity of cisplatin-contained chemotherapy regimen in cancer patients. *Biol Trace Elem Res* 1997;56:331-341.
100. Kappus H, Reinhold C. Inhibition of bleomycin-induced toxic effects by antioxidants in human malignant melanoma cells. *Adv Exp Med Biol* 1990;264:345-348.
101. Folkers K, Brown R, Judy W, Morita M. Survival of cancer patients on therapy with coenzyme Q10. *Biochem Biophys Res Comm* 1993;192:241-245.
102. Lockwood K, Moesgaard S, Yamamoto T, Folkers K. Progress on therapy of breast cancer with vitamin Q10 and the regression of metastases. *Biochem Biophys Res Comm* 1995;212:172-177.
103. Lockwood K, Moesgaard S, Hanioka T, Folkers K. Apparent partial remission of breast cancer in 'high-risk' patients supplemented with nutritional antioxidants, essential fatty acids and coenzyme Q10. *Molec Aspects Med* 1994;15:S231-S240.
104. Lund EL, Quistorff B, Spang-Thomsen M, Kristjansen PEG. Effect of radiation therapy on small-cell lung cancer is reduced by ubiquinone intake. *Folia Microbiol* 1998;43:505-506.

105. Tsubaki K, Horiuchi A, Kitani T, et al. Investigation of the preventive effect of CoQ10 against the side-effects of anthracycline antineoplastic agents. *Gan To Kagaku Ryoho* 1984;11:1420-1427.
106. Shaeffer J, El-Mahdi AM, Nichols RK. Coenzyme Q10 and adriamycin toxicity in mice. *Res Commun Chem Pathol Pharmacol* 1980;29:309-315.
107. Iarussi D, Auricchio U, Agretto A, et al. Protective effect of coenzyme Q10 on anthracyclines cardiotoxicity: control study in children with acute lymphoblastic leukemia and non-hodgkin lymphoma. *Molec Aspects Med* 1994;15:S207-S212.
108. Reiter RJ, Carneiro RC, Oh CS. Melatonin in relation to cellular antioxidative defense mechanisms. *Horm Metab Res* 1997;29:363-372.
109. Peller S. Clinical implications of p53: effect on prognosis, tumor progression and chemotherapy response. *Semin Cancer Biol* 1998;8:379-387.
110. Neri B, DeLeonardis V, Gemelli MT, et al. Melatonin as biological response modifier in cancer patients. *Anticancer Res* 1998;18:1329-1332.
111. Lissoni P, Paolorossi F, Tancini G, et al. Is there a role for melatonin in the treatment of neoplastic cachexia. *Eur J Cancer* 1996;32A:1340-1343.
112. Lissoni P, Barni S, Ardizzioia A, et al. Randomized study with the pineal hormone melatonin versus supportive care alone in advanced nonsmall cell lung cancer resistant to a first-line chemotherapy containing cisplatin. *Oncology* 1992;49:336-339.
113. Lissoni P, Barni S, Ardizzioia A, et al. A randomized study with the pineal hormone melatonin versus supportive care alone in patients with brain metastases due to solid neoplasms. *Cancer* 1994;73:699-701.
114. Lissoni P, Brivio O, Brivio F, et al. Adjuvant therapy with the pineal hormone melatonin in patients with lymph node relapse due to malignant melanoma. *J Pineal Res* 1996;21:239-242.
115. Lissoni P, Barni S, Crispino S, et al. Endocrine and immune effects of melatonin therapy in metastatic cancer patients. *Eur J Cancer Clin Oncol* 1989;25:789-795.
116. Anonymous. Evaluation of an unconventional cancer treatment (the Di Bella multitherapy): results of phase II trials in Italy. Italian Study Group for the Di Bella Multitherapy Trials. *BMJ* 1999;318:224-228.
117. Vijayalaxmi R, Meltz ML, Reiter RJ, et al. Melatonin and protection from whole-body irradiation: survival studies in mice. *Mutat Res* 1999;425:21-27.
118. Lissoni P, Meregalli S, Nosetto L, et al. Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone. *Oncology* 1996;53:43-46.
119. Lissoni P, Paolorossi F, Tancini G, et al. A phase II study of tamoxifen plus melatonin in metastatic solid tumor patients. *Br J Cancer* 1996;74:1466-1468.
120. Lissoni P, Tancini G, Paolorossi F, et al. Chemoneuroendocrine therapy of metastatic breast cancer with persistent thrombocytopenia with weekly low-dose epirubicin plus melatonin: a phase II study. *J Pineal Res* 1999;26:169-173.
121. Lissoni P, Paolorossi F, Ardizzioia A. A randomized study of chemotherapy with cisplatin plus etoposide versus chemoendocrine therapy with cisplatin, etoposide and the pineal hormone melatonin as a first-line treatment of advanced non-small cell lung cancer patients in a poor clinical state. *J Pineal Res* 1997;23:15-19.
122. Ghielmini M, Pagani O, de Jong J. Double-blind randomized study on the myeloprotective effect of melatonin in combination with carboplatin and etoposide in advanced lung cancer. *Br J Cancer* 1999;80:1058-1061.
123. Lissoni P, Barni S, Tancini G. A randomized study with subcutaneous low-dose interleukin 2 alone vs. interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma. *Br J Cancer* 1994;69:196-199.
124. Lissoni P, Meregalli S, Fossati V, et al. A randomized study of immunotherapy with low-dose subcutaneous interleukin-2 plus melatonin vs. chemotherapy with cisplatin and etoposide as first-line therapy for advanced non-small cell lung cancer. *Tumori* 1994;80:464-467.
125. Miller LF, Rumack BH. Clinical safety of high oral doses of acetylcysteine. *Sem Oncol* 1983;10:S76-S85.

126. Maasilta P, Holsti LR, Blomqvist P, et al. N-Acetylcysteine in combination with radiotherapy in the treatment of non-small cell lung cancer: a feasibility study. *Radiother Oncol* 1992;25:192-195.
127. Wanamarta AH, van Rijn J, Blank LECM, et al. Effect of N-acetylcysteine on the antiproliferative action of X-rays or bleomycin in cultured human lung cancer cells. *J Cancer Res Clin Oncol* 1989;115:340-344.
128. Kim JA, Baker DG, Hahn SS, et al. Topical use of N-acetylcysteine for reduction of skin reaction to radiation therapy. *Semin Oncol* 1983;10:S86-S88.
129. Levy L, Vredevoe DL. The effect of N-acetylcysteine on cyclophosphamide immunoregulation and antitumor activity. *Semin Oncol* 1983;10:S7-S16.
130. Harrison EF, Fuquay ME, Hunter HL. Effect of N-acetylcysteine on the antitumor activity of cyclophosphamide against Walker-256 carcinosarcoma in rats. *Semin Oncol* 1983;10:S25-S27.
131. Palermo MS, Olabuenaga SE, Giordano M, Isturiz MA. Immunomodulation exerted by cyclophosphamide is not interfered with by N-acetylcysteine. *Int J Immunopharmac* 1986;8:651-655.
132. Slavik M, Saiers JH. Phase I clinical study of acetylcysteine's preventing ifosfamide-induced hematuria. *Semin Oncol* 1983;10:S62-S65.
133. Holoye PY, Duelle J, Hansen RM, et al. Prophylaxis of ifosfamide toxicity with oral acetylcysteine. *Semin Oncol* 1983;10:S66-S71.
134. Myers C, Bonow R, Palmeri S, et al. A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. *Semin Oncol* 1983;10:S53-S55.
135. Unverferth DV, Jagadeesh JM, Unverferth BJ, et al. Attempt to prevent doxorubicin induced acute human myocardial morphologic damage with acetylcysteine. *J Natl Cancer Inst* 1983;71:917-920.
136. Olson RD, Stroo WE, Boerth RC. Influence of N-acetylcysteine on the antitumor activity of doxorubicin. *Semin Oncol* 1983;10:S29-S34.
137. Schmitt-Graff A, Scheulen ME. Prevention of adriamycin cardiotoxicity by niacin, isocitrate, or N-acetylcysteine in mice. *Path Res Pract* 1986;181:168-174.
138. Roller A, Weller M. Antioxidants specifically inhibit cisplatin cytotoxicity of human malignant glioma cells. *Anticancer Res* 1998;18:4493-4497.
139. Miyajima A, Nakashima J, Tachibana M, et al. N-acetylcysteine modifies cis-dichlorodiammineplatinum induced effects in bladder cancer cells. *Jpn J Cancer Res* 1999;90:565-570.
140. Sheikh-Hamad D, Timmins K, Jalali Z. Cisplatin-induced renal toxicity: possible reversal by N-acetylcysteine treatment. *J Am Soc Nephrol* 1997;8:1640-1644.
141. Witschi A, Reddy S, Stofer B, Lauterberg BH. The systemic availability of oral glutathione. *Eur J Clin Pharmacol* 1992;43:667-669.
142. Hagen TM, Wierzbicka GT, Sillau AH, et al. Bioavailability of dietary glutathione: effect on plasma concentration. *Am J Physiol* 1990;259:G524-G529.
143. Holroyd KJ, Buhl R, Borok Z, et al. Correction of glutathione deficiency in the lower respiratory tract of HIV seropositive individuals by glutathione aerosol treatment. *Thorax* 1993;48:985-989.
144. Hospers GAP, Eisenhauer EA, de Vries EGE. The sulfhydryl containing compounds WR-2721 and glutathione as radio- and chemoprotective agents. A review, indications for use and prospects. *Br J Cancer* 1999;80:629-638.
145. Dalhoff K, Ranek L, Mantoni M, Poulsen, HE. Glutathione treatment of hepatocellular carcinoma. *Liver* 1992;12:341-343.
146. Novi AM. Regression of aflatoxin B1-induced hepatocellular carcinomas by reduced glutathione. *Science* 1981;212:541-542.
147. Kidd PM. Glutathione: systemic protectant against oxidative and free radical damage. *Altern Med Rev* 1997;2:155-176.
148. DeMaria D, Falchi AM, Venturino P. Adjuvant radiotherapy of the pelvis with or without reduced glutathione: a randomized trial in patients operated on for endometrial cancer. *Tumori* 1992;78:374-376.
149. Meijer C, Mulder NH, de Vries EGE. The role of detoxifying systems in resistance of tumor cells to cisplatin and adriamycin. *Cancer Treat Rev* 1990;17:389-407.



150. Smyth JF, Bowman A, Parren T, et al. Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial. *Ann Oncol* 1997;8:569-573.
151. Bogliun G, Marzorati L, Marzola M, et al. Neurotoxicity of cisplatin +/- reduced glutathione in the first-line treatment of advanced ovarian cancer. *Int J Gynaecol Cancer* 1996;6:415-419.
152. Cascinu S, Cordella L, Del Ferro E, et al. Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial. *J Clin Oncol* 1995;13:26-32.
153. Di Re F, Bohm S, Oriana S, et al. High-dose cisplatin and cyclophosphamide with glutathione in the treatment of advanced ovarian cancer. *Ann Oncol* 1993;4:55-61.
154. Locatelli MC, D'Antonia A, Lablanca R, et al. A phase II study of combination chemotherapy in advanced ovarian carcinoma with cisplatin and cyclophosphamide plus reduced glutathione as potential protective agent against cisplatin toxicity. *Tumori* 1993;79:37-39.
155. Bushman JL. Green tea and cancer in humans: a review of the literature. *Nutr Cancer* 1998;31:151-159.
156. Lian F, Li Y, Bhuiyan M, Sarkar FH. P-53-independent apoptosis induced by genestein in lung cancer cells. *Nutr Cancer* 1999;33:125-131.
157. Miodini P, Fioravanti L, DiFronzo G, Cappelletti V. The two phyto-oestrogens genistein and quercetin exert different effects on oestrogen receptor function. *Br J Cancer* 1999;80:1150-1155.
158. Sriganth INP, Premalatha B. Dietary curcumin with cisplatin administration modulates tumour marker indices in experimental fibrosarcoma. *Pharmacol Res* 1999;39:175-179.
159. Zi X, Agarwal R. Silibinin decreases prostate-specific antigen with cell growth inhibition via G1 arrest, leading to differentiation of prostate carcinoma cells: implications for prostate cancer intervention. *Proc Natl Acad Sci* 1999;96:7490-7495.
160. van Rijn J, van den Berg J. Flavonoids as enhancers of x-ray-induced cell damage in hepatoma cells. *Clin Cancer Res* 1997;3:1775-1779.
161. Fritz-Niggli H, Rao KR. Rutosides and radiation induced regression of experimental tumors. *Arzn Forsch* 1977;27:1057-1064.
162. Robert J. Multidrug resistance in oncology: diagnostic and therapeutic approaches. *Eur J Clin Invest* 1999;29:536-545.
163. Sadzuka Y, Sugiyama T, Hirota S. Modulation of cancer chemotherapy by green tea. *Clin Cancer Res* 1998;4:153-156.
164. Sugiyama T, Sadzuka Y. Enhancing effects of green tea components on the antitumor activity of adriamycin against M5076 ovarian sarcoma. *Cancer Lett* 1998;133:19-26.
165. Scambia G, Ranelletti FO, Panici PB, et al. Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast cancer cell line: P-glycoprotein as a possible target. *Cancer Chemother Pharmacol* 1994;34:459-464.
166. Critchfield JW, Welsh CJ, Phang JM, Yeh GC. Modulation of adriamycin accumulation and efflux by flavonoids in HCT-15 colon cells. *Biochem Pharm* 1994;48:1437-1445.
167. Versantvoort CHM, Schuurhuis GJ, Pinedo HM, et al. Genistein modulates the decreased drug accumulation in non-P-glycoprotein mediated multidrug resistant tumour cells. *Br J Cancer* 1993;68:939-946.
168. Marverti G, Andrews PA. Stimulation of cis-diamminedichloroplatinum(II) accumulation by modulation of passive permeability with genistein: an altered response in accumulation-defective resistant cells. *Clin Cancer Res* 1996;2:991-999.
169. Hofmann J, Fiebig HH, Winterhalter BR, et al. Enhancement of the antiproliferative activity of cis-diamminedichloroplatinum(II) by quercetin. *Int J Cancer* 1990;45:536-539.
170. Scambia G, Ranelletti FO, Panici PB, et al. Inhibitory effect of quercetin on primary ovarian and endometrial cancers and synergistic activity with cis-diamminedichloroplatinum (II). *Gynecol Oncol* 1992;45:13-19.
171. Bracke ME, Depypere HT, Boterberg T, et al. Influence of tangeretin on tamoxifen's therapeutic benefit in mammary cancer. *J Natl Cancer Inst* 1999;91:354-359.
172. Schwartz JA, Liu G, Brooks SC. Genestein-mediated attenuation of tamoxifen-induced antagonism from estrogen receptor-regulated genes. *Bioch Biophys Res Comm* 1998;253:38-43.

173. Shen F, Xue X, Weber G. Tamoxifen and genistein synergistically down-regulate signal transduction and proliferation in estrogen receptor-negative human breast carcinoma MDA-MB-435 cells. *Anticancer Res* 1999;19:1657-1662.
174. Shklar G, Schwartz J, Trickler D, Reid S. Regression of experimental cancer by oral administration of combined alpha-tocopherol and beta-carotene. *Nutr Cancer* 1989;12:321-325.
175. Wagdi P, Fluri M, Aeschbacher B, et al. Cardioprotection in patients undergoing chemo- and/or radiotherapy for neoplastic disease. *Jpn Heart J* 1996;37:353-359.
176. Braverman A. Medical oncology in the 1990's. *Lancet* 1991;337:901-902.
177. Braverman A. Chemotherapeutic failure: resistance or insensitivity? *Lancet* 1980;2:1343-1346.
178. Greenberg DM. The vitamin fraud in cancer quackery. *West J Med* 1975;122:345-348.
179. Benade L, Howard T, Burk D. Synergistic killing of Ehrlich ascites carcinoma cells by ascorbate and 3-amino-1,2,4,-triazole. *Oncology* 1969;23:33-43.
180. Oberley TD, Oberley LW. Antioxidant enzyme levels in cancer. *Histol Histopathol* 1997;12:525-535.

### NOTICE OF INTENT

The American Academy of Ophthalmology's Committee on Ophthalmic Procedures Assessment Complementary Therapies Task Force will develop a Complementary Therapies Assessment (CTA) on Antioxidant Vitamin and Mineral Supplements for AMD. CTAs evaluate complementary therapies in eye care and develop an opinion on their safety and effectiveness, based on the best available evidence and scientific data.

If you are interested in bringing to the Academy's attention pertinent, scientifically-sound and evidence-based reports, references and articles (other than those which are readily available in the scientific literature) for these subjects, please forward this information to Nancy Collins in the Quality and Clinical Care Department of the American Academy of Ophthalmology, 655 Beach Street, San Francisco, CA 94109. The Academy requests the receipt of any information by November 1, 1999, for timely consideration